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Objective: While psychotic experiences (PEs) are known to be associated with a range of mental and 
general medical disorders, little is known about the association between PEs and measures of 
disability. We aimed to investigate this question using the World Mental Health surveys.  
Method: Lifetime occurrences of 6 types of PEs were assessed along with 21 mental disorders and 
14 general medical conditions. Disability was assessed with a modified version of the WHO Disability 
Assessment Schedule. Descriptive statistics and logistic regression models were used to investigate 
the association between PEs and high disability scores (top quartile) with various adjustments.    
Results:  Respondents with PEs were more likely to have top quartile scores on global disability than 
respondents without PEs (19.1% vs. 7.5%; χ2
Conclusions: Psychotic experiences are associated with disability measures with a dose response 
relationship. These results are consistent with the view that PEs are associated with disability 
regardless of the presence of comorbid mental or general medical disorders.  
 = 190.1, p<.001) as well as greater likelihood of 
cognitive, social, and role impairment.  Relationships persisted in each adjusted model. A significant 
dose-response relationship was also found for the PE type measures with most of these outcomes.  
 
Key words: Psychotic experiences, disability, World Mental Health Survey, WHODAS 
Significant outcomes 
• Respondents with psychotic experiences have a significantly increased odds of being in the 
top quartile scores on disability measures related to cognitive, social, and role impairment 
(compared to respondents without PEs). • The risk is above and beyond the risk associated with comorbid general medical and mental 
disorders.   • There was a dose response relationship between increased PE types and likelihood of 
disability 
Limitations 
• We did not have access to valid measures of clinical psychotic disorders in our sample.  
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• While we were able to assess the WHODAS for the previous 30 days, we do not have 
information on disability across the lifespan. • While cross-sectional studies cannot deduce that PEs lead to subsequent disability, some 
respondents who reported high recent disability scores may have had this level of disability 
prior to the onset of PEs.   
 
Introduction 
Approximately one in twenty people in the general community report psychotic experiences (PEs; 
which include hallucinations and delusions) at some stage in their life (1, 2).  Recent population-
based studies have found that PEs are associated with a range of mental (3, 4) and general medical 
disorders (5, 6).  Studies have also shown that those with lifetime PEs tend to have poorer functional 
outcomes, such as poorer neuropsychological functioning (7) and greater general psychological 
distress (8 , 9). Based on this evidence, it is generally believed that PEs may offer a severity marker in 
the context of other mental disorders. Thus, those with comorbid PEs and mental disorders would 
have greater impairment, which would be reflected in greater levels of disability in domains such as 
cognition (i.e. concentration, memory, thinking clearly), social interactions and the ability to work 
and/or perform normal activities.  It is also feasible that those with PEs in the absence of mental 
disorders may have impairments across a range of domains. The World Health Organisation 
Disability Assessment Schedule (WHODAS) has been proposed as the gold standard for assessing 
disability in different domains of mental and general medical disorders (10-14).  Apart from overall 
WHODAS disability scores (henceforth called global disability), there are several nested domains that 
may be particularly affected by mental disorders (compared to general medical disorders). For 
example, PEs would be more likely to disrupt domains such as cognition, social relationships and role 
functioning, more so than domains such as mobility or basic self-care.  
There is some evidence that PEs are associated with impaired functional outcomes in the young.   In 
a sample of adolescents, Kelleher et al. (15) found that those with PEs had poorer functional 
outcomes compared to those without PEs. Functional deficits in those with PEs have also been 
described among help-seeking adolescents (16) and young adults (9). A large cross-national study 
also reported a relationship between the PEs and general health status derived from 16 health-
related domains (17). There is robust evidence that individuals with psychotic disorders experience 
disability across a range of domains (13, 14, 18, 19), with recent evidence from a meta-analyses 
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indicating that those at high risk of psychosis also suffer from disability (20, 21).  Based on these 
findings, and if psychosis can be considered to occur on a continuum (22), it is reasonable to 
hypothesize that individuals with PEs but without a psychotic disorder per se are also more likely to 
have disability (compared to those without PEs).  As PEs are known to be highly comorbid with 
mental and general medical disorders (3, 5), it is expected that the association between PEs and 
disability will be influenced by the presence of such disorders (i.e. strong association between PEs 
and disability in the presence of comorbidity). Thus, multivariable models are required to 
disentangle the associations of PEs, and mental and general medical comorbidities with disability. 
We also investigated whether among respondents with one or more PEs, there was a dose-response 
relationship between the number of PE types and disability outcomes. These research questions 
were examined using data from the WHO World Mental Health (WMH) surveys, one of the largest 
datasets obtained from multiple countries with diverse cultural backgrounds.  
Aims of the study 
To examine the relationship between PEs and disability, based on the WHO World Mental Health 
(WMH) surveys, one of the largest datasets obtained from multiple countries with diverse cultural 
backgrounds.  
 
Method   
Sample 
The WMH surveys are a coordinated set of community surveys administered to probability samples 
of the non-institutionalized population in countries throughout the world 
(www.hcp.med.harvard.edu/WMH) (23). We examined the 19 WMH surveys that included both the 
CIDI Psychosis Module and the WHO Disability Schedule (WHODAS) described below. The 19 
countries are distributed across North and South America (Argentina, Brazil-Sao Paulo,, Colombia, 
Mexico, Peru, and  USA); Africa (Nigeria); the Middle East (Iraq, Lebanon); Asia (Shenzhen in the 
People’s Republic of China); the South Pacific (New Zealand), and Europe (Belgium, France, 
Germany, Italy, the Netherlands, Portugal, Romania, Spain). Most of the WMH surveys were based 
on multi-stage, clustered area probability household sampling designs except Belgium, Germany and 
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Italy which used municipal resident registries to select respondents (Supplementary table S1). The 
weighted average response rate across all 19 countries was 72.3%.  
In keeping with previous studies of PEs (2, 3, 24-26), we made the a priori decision to exclude 
individuals who had PEs but who also screened positive for possible schizophrenia/psychosis, and 
manic-depression/mania (i.e. respondents: (a) who reported (1) schizophrenia/ psychosis or (2) 
manic-depression/mania in response to the  question “What did the doctor say was causing 
(this/these) experiences?”; and (b) who ever took any antipsychotic medications for these 
symptoms). This resulted in the exclusion of 91 respondents (0.4% of all respondents), leaving 
33,370 respondents for this study.  
Procedures  
All surveys were conducted in the homes of respondents by trained lay interviewers. Informed 
consent was obtained before beginning the interview in all countries. Procedures for obtaining 
informed consent and data protection (ethical approvals) were reviewed and approved by the 
institutional review boards of the collaborating organisations in each country (27). Standardised 
interviewer training and quality control procedures were used consistently in the surveys. Full details 
of these procedures are described elsewhere (28, 29).  
All WMH interviews had two parts. Part I, administered to all respondents, assessed core mental 
disorders. Part 2, which included demographic characteristics, disability, additional mental disorders, 
and PEs, and general medical disorders, was administered to respondents who met lifetime criteria 
for a Part I disorder and a random proportion of the rest. Part 2 individuals were weighted by the 
inverse of their probability of selection to restore representativeness.  Additional weights were used 
to adjust for differential probabilities of selection within households, nonresponse, and to match the 
samples to population socio-demographic distributions.  
Data collection and data items 
The instrument used in the WMH surveys was the WHO Composite International Diagnostic 
Interview (CIDI) (29), a validated, fully-structured diagnostic interview 
(http://www.hcp.med.harvard.edu/wmhcidi/instruments_download.php) designed to assess the 
prevalence and correlates of a wide range of mental disorders according to the definitions and 
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criteria of both the DSM-IV and ICD-10 diagnostic systems. WHO translation, back-translation, and 
harmonisation protocols were used to adapt the CIDI for use in each participating country.  
Psychotic experiences (PEs) 
The CIDI Psychosis Module included questions about 6 PE types – 2 related to hallucinatory 
experiences (visual hallucinations, auditory hallucinations) and 4 related to delusional experiences 
(thought insertion/withdrawal, mind control/passivity, ideas of reference, plot to harm/follow) 
(Supplementary table S2a, S2b). Respondents were asked if they ever experienced each PE (e.g., 
“Have you ever seen something that wasn’t there that other people could not see?”; “Have you ever 
heard any voices that other people said did not exist?” etc.). Only PEs occurring when the person was 
‘not dreaming, not half-asleep, or not under the influence of alcohol or drugs’ were included. 
Respondents who reported PEs were then asked about frequency/occurrences of the PEs in their 
lifetime. In this paper, we present two key PE-related metrics: (a) number of PE types (henceforth 
referred to as PE type metric); and (b) frequency of occurrence of PE episodes. We derived 
frequency per year by dividing the number of PE episodes by the time since onset of the PEs (age at 
interview minus age of onset, henceforth referred to as annualized frequency metric (24). 
 
Disability 
Disability was assessed using a modified version of the WHO Disability Assessment Schedule II 
(WHODAS-II) for use in the WMH surveys (30, 31). The WMH-WHODAS II asked about disability in 
the 30 days prior to the interview across five domains (Supplementary table S2c): (1) Understanding 
and communicating (Cognitive), e.g.,  difficulties with concentration, memory, understanding or 
ability to think clearly; (2) Getting around (Mobility), e.g., difficulties with standing for long periods, 
moving around or getting out of their home; (3) Self-care (Self-care), e.g., difficulties with washing, 
getting dressed and feeding; (4) Getting along with others (Social interaction), e.g., difficulties with 
maintaining a normal social life or participating in social activities; and (5) Role impairment (Role 
functioning), e.g., inability to carry out normal activities, cutting back on the amount or quality of 
usual activities, extreme effort needed to perform at one’s usual level.  Global WHODAS disability is 
the mean of these five domains. Further details of the scale are presented elsewhere (31). 
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Mental disorders 
The WMH CIDI assessed lifetime history of 21 mental disorders, including mood disorders (major 
depressive episode, bipolar disorders); anxiety disorders (panic disorder, generalized anxiety 
disorder (GAD), specific phobia, social phobia, agoraphobia without panic, post-traumatic stress 
disorder (PTSD), separation anxiety disorder (SAD) further divided into childhood SAD and adult 
separation anxiety disorder); behaviour disorders (intermittent explosive disorder, attention deficit 
disorder, oppositional defiant disorder, conduct disorder); eating disorders (anorexia nervosa, 
bulimia nervosa, and binge eating disorder); and substance use disorders (alcohol abuse, alcohol  
dependence, drug  abuse, and  drug dependence). Clinical reappraisal studies indicate that lifetime 
diagnoses based on the CIDI have good concordance with diagnoses based on blinded clinical 
interviews (32).  
General medical conditions 
General medical conditions were assessed with a standard checklist based on the US National Health 
Interview Survey (33).  Fourteen conditions were assessed in this study. Specifically, respondents 
were asked whether they had a lifetime history of arthritis, stroke, back or neck pain, other chronic 
pain, chronic headaches, and seasonal allergies, and whether they were ever told by a doctor or 
other health professional that they had cancer, heart disease, high blood pressure, diabetes, 
epilepsy, peptic ulcer, asthma, or chronic lung disease. Prior research has demonstrated good 
concordance between self-report illness and medical records (34).  
Statistical Analysis 
The scores computed for each disability domain ranged from 0 to 100 (higher scores indicated 
greater disability). Because the distributions were skewed toward the very low end of the scale, each 
score was dichotomized into present (upper quartile of the distribution) and absent (bottom three 
quartiles).  A series of multivariable logistic regression models was used to investigate the 
relationship between the PEs and disability.  Analyses adjusted for country as well as: (a) socio-
demographic characteristics (gender, age at interview, education, employment history, marital 
status, household income and nativity (Model 1); b) socio-demographic characteristics and lifetime 
mental disorders (Model 2); c) socio-demographic characteristics and lifetime general medical 
conditions (Model 3), and (d) all of the above (Model 4).    
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Next, we examined whether extent of comorbidity influenced the association between PE and 
disability. We thus constructed logistic models and stratified by four levels of mental comorbidity (0, 
1, 2-3, and 4 or more), and three levels of general medical comorbidity (0, 1-2, and 3 or more) in 
predicting the disability outcomes (i.e. within the subgroup with a certain number of comorbidity 
disorders, is the presence of PEs associated with greater disability). These analyses adjusted for 
country, socio-demographic characteristics, and other mental or general medical disorders 
respectively (see details in the tables’ footnotes). Interaction models were constructed and Wald χ2 
Finally, to explore the impact of number of PEs, we restricted the analyses to those with PEs, and 
repeated the logistic regression models (adjusted models) using PE type (2 or more PE types versus 1 
PE type) and PE annualized frequency metric (median split) as predictors of disability. While the 
disability measures were based on the last 30 days, it is possible that some respondents may have 
had PE onset during the period covered by the disability assessment; we therefore undertook 
sensitivity analyses by repeating the main analyses in the subgroup with PE onset prior to the last 12 
months. 
from these models were used to examine for significant differences in the estimates within the 
varying levels of mental/general medical comorbidity. 
As the WMH data are both clustered and weighted, the design-based Taylor series linearization 
implemented in SUDAAN software was used to estimate standard errors and evaluate the statistical 
significance of coefficients.  All significance tests were evaluated using .05-level two-sided tests.  
Results 
The lifetime prevalence of PEs was 5.7% (S.E. = 0.2). Among those with PEs, 27.8% (S.E. = 1.4) 
reported more than 1 PE type (Supplementary table S3). The socio-demographic characteristics of 
respondents with (n = 2,488) and without PEs (n = 30,882) are presented in Supplementary table S4.  
One or more general medical conditions was reported by 77.5% (S.E. = 1.4) of respondents with PEs 
(77.5%, S.E. = 1.4), while the comparable proportion in those without PEs was 59.0% (S.E. = 0.4). 
Similarly, mental disorders were reported by 58.0% (S.E. = 1.8) of respondents with PEs, while the 
comparable proportion in those without PEs was 28.2% (S.E. = 0.4). 
Disability 
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Table 1 shows that apart from the self-care domain, the proportion of respondents with disability 
(top quartile of the scale) was higher in those with one or more PEs than among those without PEs. 
For example, 19.1% (S.E. =1.1) of the respondents with a PE had global disability compared to 7.5% 
(S.E. =0.2) without PEs (χ21 = 190.1, p<.001). Similarly, those with two or more PE items were more 
likely to have a disability (χ21 
INSERT TABLE 1 ABOUT HERE 
= 17.8, p<.001).  
Association between any PEs with disability  
Table 2 summarizes the associations between PEs and presence of disability. In Model 1, which 
adjusted for country and socio-demographic characteristics, PEs were significantly associated with 
an increased odds of each disability domain except self-care.  Respondents with PEs had about three 
times the odds of global disability compared to respondents with no PEs (OR=2.9, 95% CI =2.5-3.4). 
Within the five WHODAS domains, the odds ratios ranged from 1.7 to 3.9, with the highest OR 
associated with social interaction (OR=3.9, 95% CI =2.9 -5.3).  
The general pattern shown in Model 1 persisted in Models 2 and 3, which adjusted for mental health 
and general medical conditions separately, and in Model 4, which included all covariates in Models 
1-3. Thus, Model 4 indicated that after full adjustment, a significant association was found between 
PEs and global disability (OR = 1.7, 95% CI = 1.4-2.1). The associations remained significant for three 
disability domains, namely cognitive (OR = 1.8, 95% CI = 1.4-2.3), social interaction (OR = 1.9, 95% CI 
= 1.4-2.7) and role functioning (OR = 1.7, 95% CI = 1.3-2.0).  
INSERT TABLE 2 ABOUT HERE 
Table 3 presents the association between PEs and disability at different levels of mental comorbidity 
(0, 1, 2-3, 4+ mental disorders) (Models 5-8). The general pattern of the associations between PEs 
and disability remained significant and constant in each of the models. There were no significant 
group differences between the four levels of comorbidity estimates and any domains of disability 
(χ23   range between 1.6 and 7.2; all p-values were non-significant).  
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Similarly, in Table 4, when we examined the associations for individuals with different numbers of 
general medical conditions (0, 1-2 and 3+), the previously mentioned significant associations 
between any PEs and disability persisted regardless of the number of comorbid general medical 
disorders. We did not find any group differences, similar to the finding for mental disorders in Table 
3, indicating that the associations of PEs and disability were constant across number of general 
medical comorbidities.  
INSERT TABLES 3 and 4 ABOUT HERE 
In summary, we found that any PEs were associated with increased odds of disability, and that the 
significant associations between PEs and different domains of disability were constant across 
different levels of mental or general medical comorbidities.  
Association between any PE type and frequency metrics with disability  
Table 5 summarizes the associations between type and annualized frequency metrics of PEs and 
disability using similar adjustments from Model 4 in Table 2.  For type metric, there was a dose-
response relationship between number of PEs and global disability (OR = 1.5, 95% CI = 1.1-2.1) as 
well as for three of the five domains (cognitive: OR = 1.7, 95% CI = 1.1-2.6; social interaction: OR = 
1.7, 95% CI = 1.0-2.8; role functioning: OR =1.6, 95% CI = 1.1-2.4). For the annualized frequency 
metric, those with more frequent PEs (compared to those with less frequent PEs) had a greater odds 
of disability only in the social interaction domain (OR = 1.7, 95% CI = 1.0-2.9).  
INSERT TABLE 5 ABOUT HERE 
Finally, when we repeated the main analyses (as shown in Table 2) in the subgroup with PE onset 
prior to the 12 months preceding the interview, the significant associations between PEs and 
different domains of disability (Table 2) were confirmed (Supplementary table S5).  The general 
pattern of the dose response relationships between PEs and disability also persisted (data not 
shown).  
Discussion 
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Based on a cross-national analysis of 19 countries, we found that compared to individuals without 
PEs, those with PEs were significantly more likely to report one or more disabilities as measured by 
the modified WHODAS scale.  The associations persisted after adjustment for mental and general 
medical comorbidities. Among those with PEs, greater number of PEs was significantly associated 
with global disability (and three of the five specific disability domains), after adjusting for mental and 
general medical disorder comorbidities.  
As hypothesized, respondents reporting PEs were more likely to report disability on three of the five 
specific domains (cognitive, social interaction and role functioning) though not in domains related to 
self-care and mobility.  Furthermore, the general pattern of findings persisted after we adjusted for a 
comprehensive number of mental health disorders (21 DSM-IV mental disorders, including almost all 
anxiety disorders, mood and impulse control disorders, and substance-use disorders) and 14 chronic 
general medical conditions (including many chronic or relapsing diseases). These results indicate that 
PEs are associated with greater disability regardless of any co-morbid general medical or mental 
disorders. Social interaction, cognitive and role functioning were the most prominent disability 
domains associated with PEs.  Interestingly, when we repeated the main analysis in order to exclude 
those with recent onset of PEs, the general pattern of findings persisted.  The dose response 
relationship between PE type and disability also persisted. Overall, these findings lend weight to the 
hypothesis that the presence of PEs contribute to disability, regardless of the presence of comorbid 
mental and/or general medical disorders.  
Reassuringly, we found no association between PEs and impairment in self-care and mobility.  It is 
possible that those with distressing PEs, such as hallucinations, may subsequently have impaired 
concentration, just as it is possible that those with persecutory delusions may be less able to initiate 
and sustain social relationships. We hope to explore these hypotheses in future studies (i.e. 
specificity of PE subtype and disability domains).  
The findings contribute to a growing body of literature suggesting that PEs, regardless of the 
presence or absence of mental disorders, are linked to functional impairment (15). However, 
alternative hypotheses cannot be excluded. For example, birth cohort studies have found that PEs 
were more common in children with (a) lower intelligence (35),  (b) cognitive deficits such as slower 
processing speed (36), or (c) neurodevelopmental disorders including dyslexia, dyspraxia and related 
problems (37).  Thus, both PEs and disability may be downstream consequences of 
neurodevelopmental disorders (38), rather than causally related. Regardless of the causal pathways, 
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our findings indicate that those with PEs are more disabled. Apart from disability, it is important to 
recall that those with PEs are more likely to report higher levels of general psychological distress (8) 
and have an increased risk of self-harm (39).  Until we have a clearer understanding of the causal 
pathways linking PEs and disability, it would be premature to suggest that our findings have 
immediate clinical implications.  
This study has several strengths: it is based on a large sample size from a range of countries, a 
uniform methodology was used for population sampling and data collection, and innovative PE-
related metrics were used. Nevertheless, several study limitations deserve consideration. In keeping 
with other population-based surveys, evaluations relied on lay interviewers to administer the 
questionnaire, the CIDI 3.0, and there was no access to clinical validations of the presence of mental 
and general medical disorders.  We excluded those with PEs who screened positive for possible 
psychotic disorders (based on self-reported schizophrenia and bipolar diagnoses and use of 
antipsychotic medications). However, we did not have access to valid measures of clinical psychotic 
disorders in our sample, and thus it is possible that a small proportion of respondents with a clinical 
diagnosis involving psychosis were included in the analyses.  While we were able to assess the 
WHODAS for the previous 30 days, we do not have information on disability across the lifespan. 
Thus, it is feasible that some respondents who reported high recent disability scores may have had 
this level of disability prior to the onset of PEs.  Birth cohort studies will be better able to address 
this particular issue.   
In summary, our study found that compared to individuals without PEs, those with PEs were more 
likely to report disability regardless of presence or number of comorbid general medical and mental 
disorders.  There was a dose response relationship between increased PE types and likelihood of 
disability. A better understanding of the functional disability of people with PEs across the lifespan 
may help contextualize the characterization of PEs in the general population.  
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Table 1. Percentage of respondents with scores on or above the 75th percentile in WMH-WHODAS disability domains, by psychotic experiences (PEs) and related 
metrics  
PEs 
  
Global 
WHODASa 
 Disability domaina 
    Cognitive   Mobility   Self-Care   
Social 
Interaction 
  
Role 
functioning 
  %b S.E.   %b S.E.   %b S.E.   %b S.E.   %b S.E.   %b S.E. 
I. PEs                                       
No PEs (n = 30882)   7.5 0.2   1.8 0.1   2.7 0.1   0.7 0.1   0.9 0.1   6.6 0.2 
Any PEs (n = 2488)   19.1 1.1   6.9 0.6   5.0 0.6   1.1 0.3   3.5 0.4   16.3 1.1 
χ21  [p-value]   190.1* [<.001]   208.7* [<.001]   21.9* [<.001]   2.8 [0.092]   101.0* [<.001]   138.1* [<.001] 
                                      
II. PE type metric                                            
(among those with PEs) 
                                    
1 PE item (n = 1706)   16.2 1.3   4.9 0.6   4.6 0.9   0.7 0.2   2.5 0.4   13.7 1.2 
2 or more PE items (n = 782)   26.4 2.5   12.0 1.6   5.9 1.2   2.2 1.0   6.1 1.2   23.1 2.5 
χ21  [p-value]   17.8* [<.001]   31.0* [<.001]   0.7 [0.401]   10.6* [0.001]   15.3* [<.001]   17.1* [<.001] 
                                      
III. PE annualized frequency metric 
(among those with PEs) 
                                    
<= 0.3 episodes (n = 1259)    17.8 1.6   5.7 0.8   5.5 1.0   1.1 0.4   2.5 0.4   15.4 1.6 
> 0.3 episodes (n = 1229)   20.5 1.5   8.2 1.0   4.5 0.7   1.1 0.5   4.7 0.8   17.4 1.5 
χ21  [p-value]   2.1 [0.147]   5.5* [0.020]   0.7 [0.418]   0.0 [0.972]   10.1* [0.002]   1.1 [0.287] 
aScores were dichotomized and defined as a score on or above the 75th percentile of the distribution of disability. For example, 7.5% in the first cell is the proportion of respondents with 
score on or above the 75th percentile (high disability) on global WHODAS among those with no psychotic experiences. 
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bEstimates are based on weighted data 
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Table 2. Associations between psychotic experiences with disability (n = 33,370) 
Disability domaina 
  
M1: Adj for socio-
demographic 
variablesb 
  
M2: Adj for socio-
demographic 
variables + 
comorbid mental 
disordersc 
  
M3: Adj for socio-
demographic 
variables + 
comorbid general 
medical disordersd 
  
M4: Adj for socio-
demographic 
variables + 
comorbid mental 
+ general medical 
disorderse 
  OR (95% CI)   OR (95% CI)   OR (95% CI)   OR (95% CI) 
Global WHODAS   2.9* (2.5-3.4)   2.1* (1.8-2.5)   2.1* (1.8-2.5)   1.7* (1.4-2.1) 
Cognitive   3.6* (2.9-4.5)   2.2* (1.7-2.7)   2.5* (2.0-3.1)   1.8* (1.4-2.3) 
Mobility   1.7* (1.3-2.3)   1.5* (1.1-2.0)   1.3 (0.9-1.7)   1.2 (0.9-1.6) 
Self-Care   1.8 (0.9-3.7)   1.5 (0.7-2.9)   1.4 (0.7-2.9)   1.2 (0.6-2.5) 
Social interaction   3.9* (2.9-5.3)   2.1* (1.5-2.9)   2.8* (2.0-3.9)   1.9* (1.4-2.7) 
Role functioning   2.7* (2.3-3.3)   2.0* (1.7-2.5)   2.0* (1.7-2.4)   1.7* (1.3-2.0) 
OR, Odds ratio;  CI, Confidence interval 
aOutcome: WMH WHODAS domain score on or above the 75th percentile of the distribution. 
Each row in the table represents a logistic regression model of any PE (ref: no PE) as predictor of high disability. 
bM1:  All models adjusted for country and socio-demographic variables (sex, age, education, employment history, marital status, 
household income and nativity).  
cM2: All models adjusted for country, socio-demographic variables and 21 DSM-IV mental disorders (listed in supplementary table S4). 
dM3: All models adjusted for country, socio-demographic variables and 14 general medical disorders (listed in supplementary table S4). 
eM4: All models adjusted for country, socio-demographic variables, 21 DSM-IV mental disorders and 14 general medical disorders (listed in 
supplementary table S4). 
*Significant at the .05 level, 2-sided test. 
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Table 3. Associations between psychotic experiences with disability by number of comorbid mental disorders (n = 33,370) 
Disability domaina 
  
M1 from table 2          
(Adj for socio-
demographic 
variables)b 
    Among subset of respondents with   Test for the 
significance of 
differences across 
4 subsamples   
(M5-M8) 
      
M5: No comorbid 
mental disorderc 
  
M6: 1 comorbid 
mental 
disorderd 
  
M7: 2-3 comorbid 
mental 
disorderse 
  
M8: 4 or more 
comorbid 
mental 
disorderse 
  
  OR (95% CI)     OR (95% CI)   OR (95% CI)   OR (95% CI)   OR (95% CI)   X23 [P-value] 
Global WHODAS   2.9* (2.5-3.4)     2.5* (1.7-3.6)   1.5* (1.0-2.2)   2.2* (1.7-2.8)   2.1* (1.5-2.9)   7.2 [0.065] 
Cognitive   3.6* (2.9-4.5)     2.1 (1.0-4.3)   2.3* (1.4-3.8)   2.2* (1.6-3.1)   1.7* (1.2-2.5)   4.0 [0.266] 
Mobility   1.7* (1.3-2.3)     1.8 (0.9-3.3)   0.9 (0.5-1.6)   1.4 (0.9-2.1)   1.4 (0.8-2.6)   3.1 [0.369] 
Self-Care   1.8 (0.9-3.7)     1.3 (0.3-4.7)   0.2 (0.0-1.7)   3.5* (1.5-7.9)   1.4 (0.7-3.1)   3.3 [0.352] 
Social interaction   3.9* (2.9-5.3)     2.5 (1.0-6.2)   1.0 (0.4-2.6)   2.2* (1.3-3.8)   2.4* (1.5-3.8)   1.6 [0.650] 
Role functioning   2.7* (2.3-3.3)     2.4* (1.7-3.5)   1.6* (1.1-2.3)   1.9* (1.5-2.5)   1.9* (1.4-2.6)   6.5 [0.088] 
OR, Odds ratio;  CI, Confidence interval 
aOutcome: WMH WHODAS domain score on or above the 75th percentile of the distribution. 
Each row in the table represents a logistic regression model of any PE (ref: no PE) as predictor of high disability. 
b All models adjusted for country and socio-demographic variables (sex, age, education, employment history, marital status, household income and nativity).  
cM5: All models adjusted for country, socio-demographic variables in those without any comorbid mental disorder. 
dM6: All models adjusted for country, socio-demographic variables and 20 DSM-IV mental disorders in those with one comorbid mental disorder. 
eM7-8: All models adjusted for country, socio-demographic variables and 21 DSM-IV mental disorders in those with 2-3 or 4+ comorbid mental disorders. 
*Significant at the .05 level, 2-sided test 
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Table 4. Associations between psychotic experiences with disability by number of comorbid general medical disorders (n = 33,370) 
Disability domaina 
  
M1 from table 2          
(Adj for socio-
demographic 
variables)b 
  Among subset of respondents with   Test for the 
significance of 
differences 
across 3 
subsamples 
(M9-M11) 
    
M9: No comorbid 
general medical 
disordersc 
  
M10: 1-2 
comorbid 
general medical 
disordersd 
  
M11: 3 or more 
comorbid 
general medical 
disordersd 
  
  OR (95% CI)   OR (95% CI)   OR (95% CI)   OR (95% CI)   X22 P-value 
Global WHODAS   2.9* (2.5-3.4)   4.7* (2.6-8.4)   2.0* (1.5-2.5)   1.9* (1.5-2.4)   3.5 [0.177] 
Cognitive   3.6* (2.9-4.5)   3.4* (1.6-7.4)   3.4* (2.4-4.8)   2.0* (1.5-2.7)   4.4 [0.108] 
Mobility   1.7* (1.3-2.3)   3.0 (0.9-9.8)   1.6 (1.0-2.7)   1.0 (0.7-1.5)   2.0 [0.361] 
Self-Care   1.8 (0.9-3.7)   0.5 (0.0-10.4)   2.4 (0.7-8.7)   1.1 (0.5-2.4)   2.0 [0.359] 
Social interaction   3.9* (2.9-5.3)   10.4* (4.8-22.3)   2.5* (1.5-4.2)   2.2* (1.4-3.5)   5.7 [0.059] 
Role functioning   2.7* (2.3-3.3)   4.3* (2.4-7.6)   1.7* (1.3-2.3)   1.9* (1.5-2.5)   3.0 [0.223] 
OR, Odds ratio;  CI, Confidence interval 
aOutcome: WMH WHODAS domain score on or above the 75th percentile of the distribution. 
Each row in the table represents a logistic regression model of any PE (ref: no PE) as predictor of high disability. 
bAll models adjusted for country and socio-demographic variables (sex, age, education, employment history, marital status, household income and 
nativity).  
cM9: All models adjusted for country and socio-demographic variables in those without any comorbid general medical disorders. 
dM10-11: All models adjusted for country, socio-demographic variables and 14 general medical disorders in those with 1-2, 3 or more comorbid general 
medical disorders. 
*Significant at the .05 level, 2-sided test. 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Table 5. Associations between psychotic experiences (2 or more versus 1 PE type, more than 0.3 
annualized episodes versus 0.3 or less) with disability in the subgroup of those with psychotic 
experiences (n = 2,488). 
Disability domaina 
  PE type metricb   
PE annualized 
frequency metricc 
  OR (95% CI)   OR (95% CI) 
Global WHODAS   1.5* (1.1-2.1)   1.1 (0.8-1.5) 
Cognitive   1.7* (1.1-2.6)   1.0 (0.7-1.6) 
Mobility   1.2 (0.6-2.6)   1.1 (0.6-1.8) 
Self-Care   1.7 (0.6-4.5)   0.5 (0.1-1.9) 
Social interaction   1.7* (1.0-2.8)   1.7* (1.0-2.9) 
Role functioning   1.6* (1.1-2.4)   1.0 (0.7-1.4) 
OR, Odds ratio;  CI, Confidence interval 
aOutcome: WMH WHODAS domain score on or above the 75th percentile of the distribution. 
bEach row represents a logistic regression model of 2 or more PE items (ref: 1 PE item) as predictor of high disability 
(ref: non-severe) adjusting for country, socio-demographic variables, 21 DSM-IV mental disorders and 14 general 
medical disorders. 
cEach row represents a logistic regression model of 0.4 or more episodes per year (ref: <= 0.3 episodes) as predictor 
of high disability (ref: non-severe) adjusting for country, socio-demographic variables, 21 DSM-IV mental disorders 
and 14 general medical disorders. 
*Significant at the .05 level, 2-sided test. 
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